OBI-821
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for OBI-821, covering 2024-07-08 to 2025-08-03. Get the full timeline:
Most recent: Clinical Trial Update: To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]